Company: CWAN
Filing Date: 2025-02-11
Form Type: S-4
Source: 0001193125-25-023759
Chunk: 72

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-02-11
Form: S-4
Chunk 72
---
 (208) 433-1200.

Poseidon Merger Sub II, LLC

Merger Sub II is a newly formed Delaware limited liability company and indirect, wholly-owned subsidiary of Clearwater.
Merger Sub II was formed on January 3, 2025 under the name Poseidon Merger Sub II, LLC solely for the purpose of engaging in the transactions contemplated by the Merger Agreement. Merger Sub II has not carried on any business, conducted any
operations or incurred any liabilities or obligations, other than those incidental to its formation pursuant to the Merger Agreement, the performance of its obligations thereunder and matters ancillary thereto. Upon consummation of the LLC Merger,
Merger Sub II will cease to exist. Merger Sub II has its executive offices located at 777 W. Main Street, Suite 900, Boise, ID 83702, and can be reached by phone at (208) 433-1200.

43

INFORMATION ABOUT THE SPECIAL MEETING General This Proxy Statement/Prospectus is first being mailed on or about , 2025 and constitutes notice of the Special Meeting in conformity with the requirements of the DGCL and the Enfusion Bylaws (as defined below). This Proxy Statement/Prospectus is being provided to Enfusion Stockholders as part of a solicitation of proxies by the Enfusion Board for use at the Special Meeting and at any adjournments or postponements of such Special Meeting. This Proxy Statement/Prospectus provides Enfusion Stockholders with information about the Special Meeting and should be read carefully in its entirety. Date, Time and Place The Special Meeting will be held on , 2025, beginning at a.m., Central time, unless postponed to a later date, via live audio webcast at . To virtually participate in the Special Meeting, visit and enter the -digit control number provided on your proxy card or voting instruction card in order to participate in the Special Meeting. Purpose of the Special Meeting At the Special Meeting, Enfusion Stockholders will be asked to vote upon the following proposals:

| • |     | Proposal 1—The Merger Agreement Proposal: the proposal to adopt the Merger Agreement, which is                                                                                                        
 further described in the sections titled “The Transactions” and “The Merger Agreement” and a copy of which is attached to this Proxy Statement/Prospectus as Annex A, and to approve the Mergers; and |

| • |     | Proposal 2—The Adjournment Proposal: the proposal